These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 17929132)
1. Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis. Kageyama Y; Takahashi M; Nagafusa T; Torikai E; Nagano A Mod Rheumatol; 2007; 17(5):398-402. PubMed ID: 17929132 [TBL] [Abstract][Full Text] [Related]
2. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Kageyama Y; Takahashi M; Nagafusa T; Torikai E; Nagano A Rheumatol Int; 2008 Jan; 28(3):245-51. PubMed ID: 17661050 [TBL] [Abstract][Full Text] [Related]
3. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Kageyama Y; Takahashi M; Ichikawa T; Torikai E; Nagano A Clin Exp Rheumatol; 2008; 26(1):73-80. PubMed ID: 18328150 [TBL] [Abstract][Full Text] [Related]
4. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Tsukahara H; Sekine K; Uchiyama M; Kawakami H; Hata I; Todoroki Y; Hiraoka M; Kaji M; Yorifuji T; Momoi T; Yoshihara K; Beppu M; Mayumi M Pediatr Res; 2003 Sep; 54(3):419-24. PubMed ID: 12761359 [TBL] [Abstract][Full Text] [Related]
5. High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress. Tsukahara H; Shibata R; Ohta N; Sato S; Hiraoka M; Ito S; Noiri E; Mayumi M Metabolism; 2003 Dec; 52(12):1601-5. PubMed ID: 14669163 [TBL] [Abstract][Full Text] [Related]
6. The relationship of oxidative DNA damage marker 8-hydroxydeoxyguanosine and glycoxidative damage marker pentosidine. Kouda K; Nakamura H; Fan W; Horiuchi K; Takeuchi H Clin Biochem; 2001 May; 34(3):247-50. PubMed ID: 11408024 [TBL] [Abstract][Full Text] [Related]
7. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Miyata T; Ishiguro N; Yasuda Y; Ito T; Nangaku M; Iwata H; Kurokawa K Biochem Biophys Res Commun; 1998 Mar; 244(1):45-9. PubMed ID: 9514872 [TBL] [Abstract][Full Text] [Related]
8. Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Takahashi M; Suzuki M; Kushida K; Miyamoto S; Inoue T Br J Rheumatol; 1997 Jun; 36(6):637-42. PubMed ID: 9236672 [TBL] [Abstract][Full Text] [Related]
9. The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Hein GE; Köhler M; Oelzner P; Stein G; Franke S Rheumatol Int; 2005 Dec; 26(2):137-41. PubMed ID: 15580352 [TBL] [Abstract][Full Text] [Related]
10. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. de Rotte MC; de Jong PH; Pluijm SM; Calasan MB; Barendregt PJ; van Zeben D; van der Lubbe PA; de Sonnaville PB; Lindemans J; Hazes JM; de Jonge R Arthritis Rheum; 2013 Nov; 65(11):2803-13. PubMed ID: 24166792 [TBL] [Abstract][Full Text] [Related]
11. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. Torikai E; Kageyama Y; Takahashi M; Nagano A Mod Rheumatol; 2006; 16(6):350-4. PubMed ID: 17164995 [TBL] [Abstract][Full Text] [Related]
12. Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis. Chen JR; Takahashi M; Suzuki M; Kushida K; Miyamoto S; Inoue T J Rheumatol; 1998 Dec; 25(12):2440-4. PubMed ID: 9858442 [TBL] [Abstract][Full Text] [Related]
13. Increased concentrations of serum pentosidine in rheumatoid arthritis. Rodríguez-García J; Requena JR; Rodríguez-Segade S Clin Chem; 1998 Feb; 44(2):250-5. PubMed ID: 9474020 [TBL] [Abstract][Full Text] [Related]
14. Pentosidine and its deposition in renal tissue in renal transplantation. Yoshida K; Yoneda T; Fujimoto K; Hirao Y; Konishi N Transplant Proc; 2005 Dec; 37(10):4266-72. PubMed ID: 16387094 [TBL] [Abstract][Full Text] [Related]
15. Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis. Costa NT; Iriyoda TMV; Alfieri DF; Simão ANC; Dichi I Inflammopharmacology; 2018 Oct; 26(5):1151-1164. PubMed ID: 30062629 [TBL] [Abstract][Full Text] [Related]
16. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. Kageyama Y; Kobayashi H; Kato N Mod Rheumatol; 2009; 19(6):657-62. PubMed ID: 19685204 [TBL] [Abstract][Full Text] [Related]
17. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477 [TBL] [Abstract][Full Text] [Related]
18. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Müller RB; von Kempis J; Haile SR; Schiff MH Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697 [TBL] [Abstract][Full Text] [Related]
20. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE; Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]